RL
Insider
Roivant Sciences Ltd.
DirectorRoivant Sciences Ltd. (Director) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales), most often in Immunovant, Inc. (IMVT). Across 1 priced purchase filing, the average 21-session return was +5.1% from execution and +5.1% from disclosure (delay-adjusted; derived). The largest single filing was $350.0M of IMVT (16,666,666 sh × $21.00, as filed), executed Dec 12 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+5.1%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+5.1%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$350.0M
shares × price, as filed
Last traded
Dec 12 2025
Filed Dec 12 2025
Median ADV $75.6M across their filed names
Open performance→Volume by month
Buys $686.9M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
IMVTRecent filings
IMVTPURCHASE
Immunovant, Inc.
View filing →
$350.0M16,666,666 sh × $21.00
Exec Dec 12 2025
Filed Dec 12 2025 · 5:17 PM ET IMVTPURCHASE Immunovant, Inc. View filing → $336.9M
16,845,010 sh × $20.00
Exec Jan 13 2025
Filed Jan 15 2025 · 5:30 PM ET